Cargando…

Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose

BACKGROUND: Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults. METHODS: We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancest...

Descripción completa

Detalles Bibliográficos
Autores principales: Mwimanzi, Francis, Lapointe, Hope R., Cheung, Peter K., Sang, Yurou, Yaseen, Fatima, Umviligihozo, Gisele, Kalikawe, Rebecca, Datwani, Sneha, Omondi, F. Harrison, Burns, Laura, Young, Landon, Leung, Victor, Agafitei, Olga, Ennis, Siobhan, Dong, Winnie, Basra, Simran, Lim, Li Yi, Ng, Kurtis, Pantophlet, Ralph, Brumme, Chanson J., Montaner, Julio S.G., Prystajecky, Natalie, Lowe, Christopher F., DeMarco, Mari L., Holmes, Daniel T., Simons, Janet, Niikura, Masahiro, Romney, Marc G., Brumme, Zabrina L., Brockman, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750654/
https://www.ncbi.nlm.nih.gov/pubmed/35018381
http://dx.doi.org/10.1101/2022.01.06.22268745
_version_ 1784631509319155712
author Mwimanzi, Francis
Lapointe, Hope R.
Cheung, Peter K.
Sang, Yurou
Yaseen, Fatima
Umviligihozo, Gisele
Kalikawe, Rebecca
Datwani, Sneha
Omondi, F. Harrison
Burns, Laura
Young, Landon
Leung, Victor
Agafitei, Olga
Ennis, Siobhan
Dong, Winnie
Basra, Simran
Lim, Li Yi
Ng, Kurtis
Pantophlet, Ralph
Brumme, Chanson J.
Montaner, Julio S.G.
Prystajecky, Natalie
Lowe, Christopher F.
DeMarco, Mari L.
Holmes, Daniel T.
Simons, Janet
Niikura, Masahiro
Romney, Marc G.
Brumme, Zabrina L.
Brockman, Mark A.
author_facet Mwimanzi, Francis
Lapointe, Hope R.
Cheung, Peter K.
Sang, Yurou
Yaseen, Fatima
Umviligihozo, Gisele
Kalikawe, Rebecca
Datwani, Sneha
Omondi, F. Harrison
Burns, Laura
Young, Landon
Leung, Victor
Agafitei, Olga
Ennis, Siobhan
Dong, Winnie
Basra, Simran
Lim, Li Yi
Ng, Kurtis
Pantophlet, Ralph
Brumme, Chanson J.
Montaner, Julio S.G.
Prystajecky, Natalie
Lowe, Christopher F.
DeMarco, Mari L.
Holmes, Daniel T.
Simons, Janet
Niikura, Masahiro
Romney, Marc G.
Brumme, Zabrina L.
Brockman, Mark A.
author_sort Mwimanzi, Francis
collection PubMed
description BACKGROUND: Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults. METHODS: We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains from pre-vaccine up to one month following the third dose, in 151 adults aged 24–98 years who received COVID-19 mRNA vaccines. RESULTS: Following two vaccine doses, humoral immunity was weaker, less functional and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. Third doses boosted antibody binding and function to higher levels than second-doses, and induced responses in older adults that were comparable in magnitude to those in younger adults. Humoral responses against Omicron were universally weaker than against the ancestral strain after both second and third doses; nevertheless, after three doses, anti-Omicron responses in older adults reached equivalence to those in younger adults. After three vaccine doses, the number of chronic health conditions, but not age per se, was the strongest consistent correlate of weaker humoral responses. CONCLUSION: Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults.
format Online
Article
Text
id pubmed-8750654
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-87506542022-01-12 Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose Mwimanzi, Francis Lapointe, Hope R. Cheung, Peter K. Sang, Yurou Yaseen, Fatima Umviligihozo, Gisele Kalikawe, Rebecca Datwani, Sneha Omondi, F. Harrison Burns, Laura Young, Landon Leung, Victor Agafitei, Olga Ennis, Siobhan Dong, Winnie Basra, Simran Lim, Li Yi Ng, Kurtis Pantophlet, Ralph Brumme, Chanson J. Montaner, Julio S.G. Prystajecky, Natalie Lowe, Christopher F. DeMarco, Mari L. Holmes, Daniel T. Simons, Janet Niikura, Masahiro Romney, Marc G. Brumme, Zabrina L. Brockman, Mark A. medRxiv Article BACKGROUND: Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults. METHODS: We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains from pre-vaccine up to one month following the third dose, in 151 adults aged 24–98 years who received COVID-19 mRNA vaccines. RESULTS: Following two vaccine doses, humoral immunity was weaker, less functional and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. Third doses boosted antibody binding and function to higher levels than second-doses, and induced responses in older adults that were comparable in magnitude to those in younger adults. Humoral responses against Omicron were universally weaker than against the ancestral strain after both second and third doses; nevertheless, after three doses, anti-Omicron responses in older adults reached equivalence to those in younger adults. After three vaccine doses, the number of chronic health conditions, but not age per se, was the strongest consistent correlate of weaker humoral responses. CONCLUSION: Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults. Cold Spring Harbor Laboratory 2022-02-21 /pmc/articles/PMC8750654/ /pubmed/35018381 http://dx.doi.org/10.1101/2022.01.06.22268745 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Mwimanzi, Francis
Lapointe, Hope R.
Cheung, Peter K.
Sang, Yurou
Yaseen, Fatima
Umviligihozo, Gisele
Kalikawe, Rebecca
Datwani, Sneha
Omondi, F. Harrison
Burns, Laura
Young, Landon
Leung, Victor
Agafitei, Olga
Ennis, Siobhan
Dong, Winnie
Basra, Simran
Lim, Li Yi
Ng, Kurtis
Pantophlet, Ralph
Brumme, Chanson J.
Montaner, Julio S.G.
Prystajecky, Natalie
Lowe, Christopher F.
DeMarco, Mari L.
Holmes, Daniel T.
Simons, Janet
Niikura, Masahiro
Romney, Marc G.
Brumme, Zabrina L.
Brockman, Mark A.
Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose
title Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose
title_full Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose
title_fullStr Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose
title_full_unstemmed Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose
title_short Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose
title_sort older adults mount less durable humoral responses to two doses of covid-19 mrna vaccine, but strong initial responses to a third dose
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750654/
https://www.ncbi.nlm.nih.gov/pubmed/35018381
http://dx.doi.org/10.1101/2022.01.06.22268745
work_keys_str_mv AT mwimanzifrancis olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT lapointehoper olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT cheungpeterk olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT sangyurou olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT yaseenfatima olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT umviligihozogisele olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT kalikawerebecca olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT datwanisneha olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT omondifharrison olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT burnslaura olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT younglandon olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT leungvictor olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT agafiteiolga olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT ennissiobhan olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT dongwinnie olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT basrasimran olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT limliyi olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT ngkurtis olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT pantophletralph olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT brummechansonj olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT montanerjuliosg olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT prystajeckynatalie olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT lowechristopherf olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT demarcomaril olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT holmesdanielt olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT simonsjanet olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT niikuramasahiro olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT romneymarcg olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT brummezabrinal olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose
AT brockmanmarka olderadultsmountlessdurablehumoralresponsestotwodosesofcovid19mrnavaccinebutstronginitialresponsestoathirddose